T
TILT Biotherapeutics
Biotech & Life Sciences · Helsinki, Finland · Founded 2013
TILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments MoreLess
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses for the enhancement of tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results. Keywords: Pharmaceuticals and BiotechnologyBiotechnology Business, Cancer Immunotherapy, Cancer Immunotherapy Product, Cell Therapy, Oncolytic Virus, T-Cell Therapy.
Company overview
TILT Biotherapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Helsinki, Finland
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 70.0
Valuation & funding
TILT Biotherapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $25M | $99M | Lifeline Ventures · Tesi · EIC Fund · Stephen Industries | ↗ |
| GRANTOther financing | Mar 2024 | $0 | — | European Innovation Council | — |
| GRANTOther financing | Feb 2024 | $2M | — | US Department of War | ↗ |
| LATE VCOther financing | Feb 2023 | $11M | $44M | Stephen Industries · ACME Investments · EIC Fund | ↗ |
| LATE VCOther financing | Jun 2022 | $11M | $44M | Lifeline Ventures · Tesi | ↗ |
| EARLY VCOther financing | Mar 2022 | EIC Fund | — | ||
| GRANTOther financing | Mar 2022 | European Innovation Council | — | ||
| DEBTDebt | Jun 2020 | Business Finland | ↗ | ||
| LATE VCOther financing | Jun 2020 | Undisclosed | — | ||
| SEEDOther financing | Dec 2016 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $4K | 0% | −$1.8M | -39825% |
| 2025 | $4K | 0% | −$1.8M | -39825% |
| 2024 | $4K | 0% | −$1.8M | -39825% |
| 2023 | $4K | -69.2% | −$1.8M | -39825% |
| 2022 | $14K | -1400% | −$1.8M | -12253.8% |
| 2021 | −$1K | -98.4% | −$1.9M | 175700% |
| 2020 | −$70K | — | −$954K | 1354.7% |
Growth signals
TILT Biotherapeutics website traffic
Latest recorded traffic for TILT Biotherapeutics is 2.2K monthly website visits, up 29.4% over the last three months. TILT Biotherapeutics's team grew 0% over the past year.
Comparisons
TILT Biotherapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
TILT Biotherapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on TILT Biotherapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where TILT Biotherapeutics has talent and traffic
team presence
In the news
Latest news about TILT Biotherapeutics
Recent press, funding announcements, and product moves mentioning TILT Biotherapeutics — open to read from the original sources.
Market sentiment
What the market is saying about TILT Biotherapeutics
An AI-synthesized read of the highest-engagement posts about TILT Biotherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TILT Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.